真实世界脉血康胶囊联合西药治疗冠心病用药规律探析

doi:10.19803/j.1672-8629.2021.08.01

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (8): 701-704.
DOI: 10.19803/j.1672-8629.2021.08.01

• 基于真实世界的中成药联合用药方案研究专栏 • 上一篇下一篇

真实世界脉血康胶囊联合西药治疗冠心病用药规律探析

耿洪娇¹, 王娅², 章轶立¹, 谢雁鸣^1,*, 陈仁波¹, 盖国忠¹, 张文丽³

¹中国中医科学院中医临床基础医学研究所,北京 100700;
²中国中医科学院西苑医院,北京 100091;
³中国人民大学统计学院,北京 100872

收稿日期:2021-02-26 出版日期:2021-08-15 发布日期:2021-08-17
通讯作者: ^*谢雁鸣,女,首席研究员·博导,中药上市后评价研究及老年病的中医诊疗规律研究。E-mail：ktzu2018@163.com
作者简介:耿洪娇,女,在读博士,中医脑病。
基金资助:
国家重点研发计划（2018YFC1707400）

Real-World Study on Use of Maixuekang Capsules Combined with Western Medicines in Treating Coronary Heart Disease

GENG Hongjiao¹, WANG Ya², ZHANG Yili¹, XIE Yanming^1,*, CHEN Renbo¹, GAI Guozhong¹, ZHANG Wenli³

¹Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China;
²Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, Beijing 100091, China;
³School of Statistics, Renmin University of China, Beijing 100872, China

Received:2021-02-26 Online:2021-08-15 Published:2021-08-17

摘要/Abstract

摘要： 目的通过对真实世界中冠心病患者应用脉血康胶囊与西药的相关性分析,探析中西药联用规律,以期为冠心病的中西医结合治疗方案提供客观依据。方法提取2006年至2016年全国22家三级甲等医院信息系统数据库中服用脉血康胶囊的冠心病住院患者医疗数据,对脉血康胶囊与西药进行关联规则分析。结果脉血康胶囊在治疗冠心病时最常与阿司匹林、硝酸异山梨酯、前列地尔、硝苯地平、美托洛尔等西药联合应用,联合应用西药的药理类型以抗凝药、血管活性药、钙离子拮抗剂以及抗高血压药为主。结论真实世界冠心病治疗中,脉血康胶囊常与常规西药联合应用,且用药方案符合临床指南推荐。

关键词: 脉血康胶囊, 冠心病, 关联规则, 真实世界研究

Abstract: Objective To analyze the combined use of Maixuekang capsules with western medicines in patients with coronary heart disease in the real world in order to provide data for the treatment of coronary heart disease with integrated traditional Chinese and western medicines. Methods The medical data on coronary heart disease inpatients who took Maixuekang capsules was retrieved from the information system database of 22 tertiary hospitals across the country from 2006 to 2016, and the association between Maixuekang capsules and western medicines was analyzed. Results Maixuekang capsules were most commonly used in combination with such western medicines as aspirin, isosorbide dinitrate, alprostadil, nifedipine and metoprolol in the treatment of coronary heart disease. The pharmacological types of western medicines were anticoagulants, vascular active drugs, calcium ion antagonists and antihypertensive drugs. Conclusion Maixuekang capsules are often used in combination with conventional western medicines in the treatment of coronary heart disease in the real world, and the medication regimens comply with clinical guidelines.

Key words: Maixuekang capsules, coronary heart disease, association rules, real world research

中图分类号:

R994.11

耿洪娇, 王娅, 章轶立, 谢雁鸣, 陈仁波, 盖国忠, 张文丽. 真实世界脉血康胶囊联合西药治疗冠心病用药规律探析[J]. 中国药物警戒, 2021, 18(8): 701-704.

GENG Hongjiao, WANG Ya, ZHANG Yili, XIE Yanming, CHEN Renbo, GAI Guozhong, ZHANG Wenli. Real-World Study on Use of Maixuekang Capsules Combined with Western Medicines in Treating Coronary Heart Disease[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 701-704.

参考文献

[1] Chen WW, Gao RL, Liu LS, et al.Summary of Chinese cardiov-ascular disease report 2016[J]. Chinese Journal of Circulation(中国循环杂志), 2017, 32(6): 521-530.
[2] Chen KT.Clinical study of Shuxinjiedu ointment for external treatment of coronary heart disease and angina pectoris[D]. Guang-zhou: Guangzhou University of Traditional Chinese Medicine, 2011.
[3] Gao S, Zhu Y.Systematic evaluation and meta analysis of the efficacy of integrated traditional Chinese and western medicine in the treatment of phlegm-turbid coronary heart disease[J]. World Journal of Integrated Traditional Chinese and Western Medicine(世界中西医结合杂志), 2018, 13(7): 909-913.
[4] Li SP, Li HX, Chen XL, et al.Effects of Maixuekang combined with cisplatin on the growth of subcutaneously transplanted tumors in nude mice bearing MHCC97H human liver cancer[J]. Chinese Journal of Traditional Chinese Medicine(中华中医药学刊), 2010, 28(9) : 1935-1937.
[5] Greinacher A, Warkentin TE.The direct thrombin inhibitor hirudin[J]. Thromb Haemost, 2008, 99(5) : 819-829.
[6] Mo W, Zhang YL, Chen HS, et al.A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition[J]. J Thromb Thrombolysis, 2009, 28(2) : 230-237.
[7] Ge CJ, Yuan CT, Sun ZY, et al.The effect of Maixuekang capsule combined with rosuvastatin on the severity of coronary artery disease in patients with borderline coronary disease[J]. Chinese Journal of Integrated Traditional Chinese and Western Medicine(中国中西医结合杂志), 2020, 40(1): 35-40 .
[8] Fuchs J, Cannon CP.Hirulog in the treatment of unstable angina: result of the thrombin inhibition in myocardial ischemia(TIMI) 7 trial[J]. Circulation, 1995, 92(4): 727.
[9] Zhuang Y, Xie BT, Weng SX, et al.Discussion on the design method of evaluating HIS "real world" integrated data warehouse after the market of traditional Chinese medicine[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2011, 36(20): 2880.
[10] Ge JB, Xu YJ, Wang C. Internal Medicine(内科学)[M]. 9th Ed. Beijing: People's Medical Publishing House, 2018: 218.
[11] World Health Organization.International Statistical Classification of Diseases and Related Health Problems (10th Revision)(国际疾病分类标准编码) [M]. 2th ed. Beijing: People's Medical Publishing House, 2008.
[12] Liu ML, Zhang XY, Ding L, et al.Application and progress of data mining methods in the study of the compatibility of traditional Chinese medicine[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2021, 32(2): 182-189.
[13] Liu L, Fu XJ, Li XB, et al.Bibliometrics analysis of cnki data mining of traditional chinese medicine[J]. World Science and Technology-Modernization of Traditional Chinese Medicine(世界科学技术-中医药现代化), 2020, 22(11): 3887-3893.
[14] Zhu MB.Introduction to Data Mining(数据挖掘导论)[M]. Hefei: University of Science and Technology of China Press, 2011: 102.
[15] Zhao L, Wang PK.Discovery of association rules: a review[J].Computer Engineering and Applications(计算机工程与应用), 2001, 37(8): 94-96.
[16] Wu XD, Zeng YZ.Data mining of college students' performance based on Apriori algorithm[J]. Journal of Langfang Teachers College (Natural Science Edition)(廊坊师范学院学报(自然科学版)), 2019, 19(1): 31-36.
[17] National Health and Family Planning Commission, Rational Drug Use Expert Committee, Chinese Pharmacists Association. Guidelines for rational use of drugs for coronary heart disease (Second Edition)[J].Frontier Journal of Chinese Medicine (Electronic Edition)(中国医学前沿杂志(电子版)), 2018, 10(6): 1-130.
[18] Zhou JL.Efficacy of maixuekang capsule in treating unstable angina pectoris of coronary heart disease[J]. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine(深圳中西医结合杂志), 2019, 29(12): 59-60.
[19] Zhang ZZ.Research progress in modern pharmacology of leeches[J]. Digest of World Latest Medical Information(世界最新医学信息文摘), 2013, 17(13): 247.
[20] Li L, Yu X, Li Y, et al.Clinical study of Maixuekang capsules in the treatment of microvascular angina pectoris[J]. Clinical Journal of Chinese Medicine(中医临床研究), 2017, 9(24): 23-24.
[21] Rao HP.Efficacy of Maixuekang capsule in the treatment of middle-aged and elderly patients with coronary heart disease and angina pectoris[J]. Electronic Journal of Integrated Traditional Chinese and Western Medicine Cardiovascular Diseases(中西医结合心血管病电子杂志), 2016, 4(30): 56-57.
[22] Ge CJ, Lu SZ, Liu H, et al.Effects of Maixuekang capsule on the platelet aggregation rate and long-term prognosis of patients with acute coronary syndrome treated by percutaneous coronary intervention[J]. Chinese Journal of Integrated Traditional Chinese and Western Medicine(中国中西医结合杂志), 2012, 32(7): 906-909.
[23] Lemesle G, de Labriolle A, Bonello L, et al. Incidence, predictors, and outcome of new, subsequent lesions treated with percutaneous coronary intervention in patients presenting with myocardial infarction[J]. Am J Cardial, 2009(103): 1189-1195.
[24] Gao LJ, Yang Q, Wang Z, et al.Effects of Maixuekang capsule on lipid metabolism and expression of adhesion molecules in hyperlipidemia rats[J]. Chinese Patent Medicine(中成药), 2013, 35(1): 1-5.
[25] Wang D.Effects of Maixuekang capsule combined with percuta-neous coronary intervention on platelet aggregation rate and high-sensitivity C-reactive protein in patients with acute coronary syndrome[J]. Journal of Practical Clinical Medicine(实用临床医药杂志), 2018, 22(5): 42-44.
[26] Luo CF.The effect of Maixuekang capsule combined with aspirin secondary prevention on carotid atherosclerosis in patients with myocardial infarction[J]. Clinical Medicine(临床医学), 2019, 39(7): 82-85.
[27] Chao TT, Zhang DW, Wang CL.Meta analysis of Maixuekang capsule combined with conventional western medicine in the treatment of unstable angina pectoris[J]. Chinese New Drugs and Clinical Pharmacology(中药新药与临床药理), 2021, 32(1): 128-134.

真实世界脉血康胶囊联合西药治疗冠心病用药规律探析

Real-World Study on Use of Maixuekang Capsules Combined with Western Medicines in Treating Coronary Heart Disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	成冯镜茗, 吕健, 谢雁鸣. 复方丹参喷雾剂/气雾剂治疗冠心病心绞痛有效性与安全性的Meta分析[J]. 中国药物警戒, 2023, 20(5): 536-543.
[2]	杜莹, 谢雁鸣, 王连心, 耿洪娇, 李向杰. 真实世界连花清瘟胶囊（颗粒）适应证人群临床特征及联合用药分析[J]. 中国药物警戒, 2023, 20(3): 296-300.
[3]	王嘉熙, 郭代红, 张博, 李伯妍, 郭海丽. 116097例氟比洛芬酯用药人群的急性肾损伤自动监测研究及危险因素分析[J]. 中国药物警戒, 2023, 20(2): 201-205.
[4]	丁倩, 李博宇, 张青霞. 阿司匹林片致冠心病患者出血性甲状腺肿大1例分析[J]. 中国药物警戒, 2023, 20(2): 209-212.
[5]	赵晓晓, 谢雁鸣, 王连心. 真实世界榄香烯乳状注射液治疗肺癌临床应用特征研究[J]. 中国药物警戒, 2022, 19(9): 940-946.
[6]	董晗硕, 孙莉, 赵晓晓, 王连心, 余小康, 谢雁鸣. 真实世界榄香烯乳状注射液用于老年人群的临床特征及联合用药分析[J]. 中国药物警戒, 2022, 19(8): 845-850.
[7]	孙春全, 谢雁鸣, 侯恒悦. 4832例生脉注射液治疗心力衰竭患者临床特征及联合用药数据挖掘[J]. 中国药物警戒, 2022, 19(2): 130-133.
[8]	程序, 张利丹, 谢雁鸣, 高阳, 杨云云. 丹参川芎嗪注射液治疗冠心病合并高血压病联合用药的复杂网络分析[J]. 中国药物警戒, 2022, 19(12): 1325-1331.
[9]	魏瑞丽, 赵晓晓, 席俊羽, 谢雁鸣. 真实世界榄香烯乳状注射液治疗恶性肿瘤联合用药规律[J]. 中国药物警戒, 2022, 19(11): 1206-1212.
[10]	姚亚敏, 姚迪, 陈燕秋, 刘力. 基于医院信息系统真实世界生脉注射液临床用药特征分析[J]. 中国药物警戒, 2021, 18(9): 876-879.
[11]	成冯镜茗, 王连心, 谢雁鸣, 庄严. 脉络舒通丸治疗骨外科疾病真实世界用药特征分析[J]. 中国药物警戒, 2021, 18(8): 710-714.
[12]	张利丹, 谢雁鸣, 谢瑀婷. 真实世界的茵栀黄颗粒临床联合用药特征分析[J]. 中国药物警戒, 2021, 18(8): 705-709.
[13]	刘玉强, 乔瑞, 卓琳, 孟若谷, 孙凤, 詹思延. 真实世界数据在上市后药品安全性研究中的伦理风险[J]. 中国药物警戒, 2021, 18(7): 628-631.
[14]	董敏, 邹彤, 徐蕾, 何清华, 裴作为, 汪芳. 多重用药对老年冠心病合并心房颤动患者远期预后的影响[J]. 中国药物警戒, 2021, 18(2): 126-132.
[15]	张广辉, 孙粼希, 吴显文, 谢雁鸣, 耿洪娇, 杨晓晨. 巢氏病例对照联合SMOTE算法分析注射用灯盏花素肾功能异常影响因素[J]. 中国药物警戒, 2021, 18(12): 1150-1154.